AU2011249859B2 - Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase - Google Patents

Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase Download PDF

Info

Publication number
AU2011249859B2
AU2011249859B2 AU2011249859A AU2011249859A AU2011249859B2 AU 2011249859 B2 AU2011249859 B2 AU 2011249859B2 AU 2011249859 A AU2011249859 A AU 2011249859A AU 2011249859 A AU2011249859 A AU 2011249859A AU 2011249859 B2 AU2011249859 B2 AU 2011249859B2
Authority
AU
Australia
Prior art keywords
ksc
formula
nmr
mhz
cpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011249859A
Other languages
English (en)
Other versions
AU2011249859A1 (en
Inventor
Jeffrey Aube
Tsui-Fen Chou
Raymond J. Deshaies
Kevin J. Frankowski
Samuel W. Gerritz
Kelin Li
Frank J. Schoenen
Han-Jie Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute of Technology
University of Kansas
Cleave Biosciences Inc
Original Assignee
California Institute of Technology
University of Kansas
Cleave Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute of Technology, University of Kansas, Cleave Biosciences Inc filed Critical California Institute of Technology
Publication of AU2011249859A1 publication Critical patent/AU2011249859A1/en
Application granted granted Critical
Publication of AU2011249859B2 publication Critical patent/AU2011249859B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2011249859A 2010-05-07 2011-05-06 Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase Ceased AU2011249859B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33266710P 2010-05-07 2010-05-07
US61/332,667 2010-05-07
PCT/US2011/035654 WO2011140527A2 (en) 2010-05-07 2011-05-06 Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase

Publications (2)

Publication Number Publication Date
AU2011249859A1 AU2011249859A1 (en) 2012-12-20
AU2011249859B2 true AU2011249859B2 (en) 2014-07-03

Family

ID=44904519

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011249859A Ceased AU2011249859B2 (en) 2010-05-07 2011-05-06 Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase

Country Status (8)

Country Link
US (1) US8865708B2 (cg-RX-API-DMAC10.html)
EP (1) EP2566480A4 (cg-RX-API-DMAC10.html)
JP (1) JP2013530942A (cg-RX-API-DMAC10.html)
KR (1) KR20130128308A (cg-RX-API-DMAC10.html)
CN (1) CN103068393A (cg-RX-API-DMAC10.html)
AU (1) AU2011249859B2 (cg-RX-API-DMAC10.html)
CA (1) CA2798698A1 (cg-RX-API-DMAC10.html)
WO (1) WO2011140527A2 (cg-RX-API-DMAC10.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013530942A (ja) 2010-05-07 2013-08-01 カリフォルニア・インスティチュート・オブ・テクノロジー 移行型小胞体ａｔｐアーゼの阻害のための方法および組成物
US8906918B1 (en) * 2012-03-23 2014-12-09 University Of South Florida (A Florida Non-Profit Corporation) Compositions, methods of use, and methods of treatment
NZ705040A (en) * 2012-07-20 2017-07-28 Cleave Biosciences Inc Fused pyrimidines as inhibitors of p97 complex
EP2938610A2 (en) 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
UA116571C2 (uk) 2013-07-16 2018-04-10 Басф Се Гербіцидні азини
DE102013110714A1 (de) * 2013-09-27 2015-04-02 Eberhard Karls Universität Tübingen Medizinische Fakultät Prophylaxe und Behandlung einer nicht auf einer Proteinfaltungsstörung beruhenden neurodegenerativen Erkrankung
US10220034B2 (en) 2013-10-18 2019-03-05 Indiana University Research And Technology Corporation Hepatitis B viral assembly effectors
US9868722B2 (en) 2013-12-10 2018-01-16 Cleave Biosciences, Inc. Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex
US9828363B2 (en) 2014-01-20 2017-11-28 Cleave Biosciences, Inc. Fused pyrimidines as inhibitors of P97 complex
US10941122B2 (en) 2014-04-11 2021-03-09 Basf Se Diaminotriazine derivatives as herbicides
CR20160545A (es) 2014-04-23 2017-03-31 Basf Se Compuestos de diaminotriazina como herbicidas
EP3134391A1 (en) * 2014-04-23 2017-03-01 Basf Se Diaminotriazine compounds and their use as herbicides
WO2016168619A1 (en) 2015-04-17 2016-10-20 Indiana University Research And Technology Corporation Hepatitis b viral assembly effectors
CN106518849B (zh) * 2016-10-27 2019-08-16 上海人类基因组研究中心 喹唑啉类化合物及其制备方法和用途
US20230096028A1 (en) * 2019-03-01 2023-03-30 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
EP4617262A1 (en) * 2022-11-07 2025-09-17 Kyoto University Nitrogen-containing heterocyclic compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025406A1 (en) * 2004-07-06 2006-02-02 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c- Met activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2071484T3 (es) 1991-02-20 1995-06-16 Pfizer Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
AU2003255482A1 (en) * 2002-10-02 2004-04-23 Merck Patent Gmbh Use of 4 amino-quinazolines as anti cancer agents
WO2006105056A2 (en) * 2005-03-28 2006-10-05 Fmc Corporation Insecticidal 2,4-diaminoquinazolines and related derivatives
WO2007041282A2 (en) * 2005-09-29 2007-04-12 The Johns Hopkins University Methods and compositions for treatment of cystic fibrosis
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
CA2691932A1 (en) * 2007-06-27 2008-12-31 Summit Corporation Plc Use of compounds for preparing anti-tuberculosis agents
US8637560B2 (en) * 2007-07-18 2014-01-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Imidazolidinone compounds, methods to inhibit deubiquitination and methods of treatment
US9089572B2 (en) * 2008-01-17 2015-07-28 California Institute Of Technology Inhibitors of p97
WO2010003908A1 (en) * 2008-07-08 2010-01-14 Jakobsson, Andreas Screening assay for compounds targeting the p97 aaa-atpase complex in the ubiquitin proteasome system.
JP2013530942A (ja) 2010-05-07 2013-08-01 カリフォルニア・インスティチュート・オブ・テクノロジー 移行型小胞体ａｔｐアーゼの阻害のための方法および組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025406A1 (en) * 2004-07-06 2006-02-02 Angion Biomedica Corporation Modulators of hepatocyte growth factor/c- Met activity

Also Published As

Publication number Publication date
KR20130128308A (ko) 2013-11-26
EP2566480A4 (en) 2014-03-19
US8865708B2 (en) 2014-10-21
WO2011140527A2 (en) 2011-11-10
WO2011140527A3 (en) 2012-03-29
JP2013530942A (ja) 2013-08-01
EP2566480A2 (en) 2013-03-13
CN103068393A (zh) 2013-04-24
CA2798698A1 (en) 2011-11-10
AU2011249859A1 (en) 2012-12-20
US20110288082A1 (en) 2011-11-24

Similar Documents

Publication Publication Date Title
AU2011249859A1 (en) Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase
AU2016207168B2 (en) Quinazoline heterocyclic compound as EGFR kinase inhibitor, and preparation and application thereof
CN104470902B (zh) N‑(3‑杂芳基芳基)‑4‑芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
CN111138358B (zh) Usp8抑制剂及其制备方法与应用
AU2005304040A1 (en) Aminoquinazolines compounds
HUP0302615A2 (hu) Kináz inhibitor kinazolinszármazékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
JP5897566B2 (ja) 環式ｎ，ｎ’−ジアリールチオ尿素及びｎ，ｎ’−ジアリール尿素−アンドロゲン受容体アンタゴニスト、抗癌剤、その調製のための方法及び使用
CA2763536C (en) Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria
BR122020004679B1 (pt) Composição farmacêutica
EP3160948B1 (en) Benzoxazinone amides as mineralocorticoid receptor modulators
US20200165257A1 (en) Inhibitors of phosphoinositide 3-kinase and histone deacetylase for treatment of cancer
CN116354901B (zh) 一种噻唑烷二酮类化合物及其制备方法和应用
Hu et al. Design, synthesis and biological evaluation of novel 2, 4-diaminopyrimidine derivatives as potent antitumor agents
EP3760633B1 (en) Oxazino-quinazoline and oxazino-quinazoline type compound, preparation method therefor, and uses thereof
EP1716867A1 (en) Preventives for migraine
CN113912595A (zh) 一类含有噻唑或噻二唑结构的化合物及其应用
EP3733186B1 (en) Novel dihydroquinazolinone compound or pharmacologically acceptable salt, and cell growth inhibitor
CN116348114B (zh) 硫代苯并咪唑衍生物或其药学上可接受的盐及其用途
EP1963328B1 (en) Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
CN101365702B (zh) 半胱氨酸蛋白酶抑制剂、其药物组合物及其治疗应用
CN104016878B (zh) 芳基乙酸类衍生物、其制备方法及其医药用途
CA2667839C (en) Novel tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications
RU2481349C2 (ru) Новые тетрациклические ингибиторы цистеиновых протеаз, их фармацевтические композиции и области их терапевтического применения
CN122036715A (zh) 一种含苯联杂芳基的2,4-二芳氨基嘧啶衍生物及其药物组合物与应用
WO2000050420A1 (fr) Derives d'acide 7-heteroquinoxaline carboxilique 6-substitue et leurs sels d'addition, procedes de preparation de ces derives et de leurs sels d'addition

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired